Viking Therapeutics completed enrollment in its Phase 2 trial and initiated the VANQUISH Phase 3 registration program for its drug VK2735.
2 reports, 1 independent
Updated Jul 24
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viking Therapeutics completed enrollment in its Phase 2 trial and initiated the VANQUISH Phase 3 registration program for its drug VK2735.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
Coverage
Newest first; wire copies grouped- GuruFocus.comViking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: Navigating Increased R&D ... Research and Development Expenses: $60.2 million for Q2 2025, up from $23.8 million in Q2 2024. General a
- Unknown outlet